- Home
- CRF vs BBNX Comparison
CRF vs BBNX Comparison
Compare CRF & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRF | BBNX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.4M | 997.9M |
| IPO Year | 1997 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CRF | BBNX |
|---|---|---|
| Price | $5.80 | $18.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $24.24 |
| AVG Volume (30 Days) | ★ 1.2M | 919.7K |
| Earning Date | 01-01-0001 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 78.95 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $100,251,000.00 |
| Revenue This Year | N/A | $25.74 |
| Revenue Next Year | N/A | $44.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.94 |
| 52 Week Low | $5.82 | $8.80 |
| 52 Week High | $8.16 | $32.71 |
Technical Indicators
Market Signals| Indicator | CRF | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 30.50 | 54.20 |
| Support Level | N/A | $15.92 |
| Resistance Level | $6.24 | $20.48 |
| Average True Range (ATR) | 0.11 | 0.96 |
| MACD | -0.02 | 0.14 |
| Stochastic Oscillator | 0.00 | 86.96 |
Price Performance
Historical ComparisonAbout CRF Cornerstone Total Return Fund Inc. (The)
Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology, Health Care, Financials, Communication Services, Consumer Discretionary, Industrials, Exchange-Traded Funds, Utilities, Energy, Real Estate, and others.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.